Unlikely. The company will continue to bleed even during restructuring.
It is more likely the company will be ripped apart and the corpse picked apart for everything it is worth. The technology will be backed into Orbimed and Amgen and the company will cease to exist.
They simply have too much debt and cash burn to make it a viable option to keep the business running. There will be a far greater return on investment taking ownership of Unilife IP, liquidating all other assets to repay the most important debts accordingly and declaring bankruptcy. The loan will see them through liquidation and paying out employee entitlements.
